Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2415
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen ; volume:18 ; number:1 ; day:20 ; month:6 ; year:2018 ; pages:1-9 ; date:12.2018
BMC ophthalmology ; 18, Heft 1 (20.6.2018), 1-9, 12.2018
- Creator
-
Lai, Kunbei
- Contributor
-
Li, Ying
Zhou, Lijun
Zhong, Xiaojin
Huang, Chuangxin
Xu, Fabao
Lu, Lin
Ge, Jian
Jin, Chenjin
SpringerLink (Online service)
- DOI
-
10.1186/s12886-018-0801-7
- URN
-
urn:nbn:de:101:1-2018083022295003344852
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lai, Kunbei
- Li, Ying
- Zhou, Lijun
- Zhong, Xiaojin
- Huang, Chuangxin
- Xu, Fabao
- Lu, Lin
- Ge, Jian
- Jin, Chenjin
- SpringerLink (Online service)
Other Objects (12)
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Delay-induced oscillation phenomenon of a delayed finance model in enterprise operation
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Manufacturable pattern collage along a boundary
Idiopathic pigmented vitreous cyst without autofluorescence: a case report
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Delay-induced oscillation phenomenon of a delayed finance model in enterprise operation
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Manufacturable pattern collage along a boundary
Idiopathic pigmented vitreous cyst without autofluorescence: a case report
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Delay-induced oscillation phenomenon of a delayed finance model in enterprise operation
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Manufacturable pattern collage along a boundary
Idiopathic pigmented vitreous cyst without autofluorescence: a case report
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy